IE
OLMA icon

Israel Englander’s Olema Pharmaceuticals OLMA Stock Holding History

Israel Englander’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$276K – 7203
2021
Q3 		$276K Buy
+10,000
New +$270K ﹤0.01% 5875

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's OLMA Position: Q2 2026 in Review

Israel Englander sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 182,935 shares — an estimated $2.73M sold.

Israel Englander first reported a position in OLMA in Q4 2020 and held it in 18 quarters. The position peaked at $12.5M in Q4 2025. 183 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Israel Englander reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 182,935 Olema Pharmaceuticals shares in Q2 2026, an estimated $2.73M.
  • Israel Englander first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 18 quarters.
  • Israel Englander's Olema Pharmaceuticals position peaked at $12.5M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.